Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study

This publication has 16 references indexed in Scilit:

• Exploring the best treatment options for BRAF-mutant metastatic colon cancer
  British Journal of Cancer, 2019
• Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
  ESMO Open, 2019
• Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)
  Journal of Clinical Oncology, 2019
• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2018
• Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
  Cancer Cell, 2018
• ^Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2017
• BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
  Clinical Cancer Research, 2017
• Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
  JNCI: Journal of the National Cancer Institute, 2016
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
  Annals of Oncology, 2016
• Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
  Cancer, 2011